Magurol tablets are indicated for:
Arterial hypertension. Benign prostatic hyperplasia.
Composition
Active ingredient: doxazosin;
1 tablet contains doxazosin mesylate 4.86 mg equivalent to doxazosin 4 mg;
Excipients: lactose monohydrate, microcrystalline cellulose, sodium starch (type A), magnesium stearate, sodium lauryl sulfate.
Contraindication
hypersensitivity to the active substance or to quinazoline derivatives or to any of the excipients listed in section; cases of orthostatic hypotension in the anamnesis of BPH and concomitant upper urinary tract obstruction, chronic urinary tract infections and the presence of bladder stones; during breastfeeding (only when used for the treatment of arterial hypertension), arterial hypotension (applies only to patients with BPH);
Doxazosin as monotherapy is contraindicated in patients with bladder overactivity or anuria with or without progressive renal insufficiency.
Method of application
The drug can be taken both in the morning and in the evening.
The drug is administered orally.
Arterial hypertension. The drug should be used once a day. The initial dose is 1 mg to minimize the risk of orthostatic hypotension and / or syncope. After 1-2 weeks of initial therapy, the dose can be increased to 2 mg, and then, if necessary, to 4 mg. In most patients, the response to therapy is observed when using the drug at a dose of 4 mg or lower. If necessary, the dose can be increased to 8 mg up to the maximum recommended dose of 16 mg.
Benign prostatic hyperplasia. The recommended initial dose of doxazosin is 1 mg once daily to minimize the risk of orthostatic hypotension and/or syncope. Depending on the individual patient's urodynamics and symptoms of BPH, the dose may be increased to 2 mg, then to 4 mg and to the maximum recommended dose of 8 mg. The recommended dose adjustment interval is 1-2 weeks. The recommended dose is 2-4 mg per day.
Application features
Pregnant women
The drug should be used only when the potential benefits of treatment, in the opinion of the physician, justify the potential risk.
Children
The safety and efficacy of the drug in children have not been studied.
Drivers
The ability to drive and use machines may be impaired, especially at the beginning of treatment.
Overdose
If an overdose of the drug has led to hypotension, the patient should be urgently placed on his back with his head down. In some cases, other symptomatic measures may be taken.
If symptomatic measures are not sufficient, shock should be treated first with plasma substitutes. Then, if necessary, vasoconstrictors should be used. Renal function should be monitored and supportive measures should be applied if necessary.
Hemodialysis is indicated because doxazosin is highly bound to plasma proteins.
Side effects
Infections and infestations: respiratory tract infections, urinary tract infections. Blood and lymphatic system disorders: leukopenia, thrombocytopenia. Immune system disorders: allergic reactions. Metabolic and nutritional disorders: gout, increased appetite, lack of appetite. Mental disorders: agitation, depression, anxiety, insomnia, nervousness. Nervous system disorders: drowsiness, dizziness, headache, stroke, hypoesthesia, syncope, tremor, orthostatic dizziness, paresthesia. Vision disorders: blurred vision, intraoperative atonic iris syndrome. Hearing and balance disorders: vertigo, tinnitus. Cardiac disorders: tachycardia, tachycardia, angina pectoris, myocardial infarction, bradycardia, arrhythmia. Vascular disorders: hypotension, orthostatic hypotension, hot flashes. Respiratory, thoracic and mediastinal disorders: bronchitis, cough, shortness of breath, rhinitis, epistaxis, exacerbation of existing bronchospasm. Gastrointestinal disorders: abdominal pain, dyspepsia, dry mouth, nausea, constipation, flatulence, vomiting, gastroenteritis, diarrhea. Digestive system: abnormal liver function tests, cholestasis, hepatitis, jaundice. Skin and subcutaneous tissue disorders: itching, rash, urticaria, alopecia, purpura. Musculoskeletal and connective tissue disorders: back pain, muscle pain, joint pain, muscle spasms, muscle weakness. From the kidneys and urinary system: cystitis, urinary incontinence, dysuria, frequent urination, hematuria, polyuria, increased diuresis, urination disorders, nocturia. From the reproductive system and mammary glands: impotence, gynecomastia, priapism, retrograde ejaculation. Interactions The combined use of doxazosin with PDE-5 inhibitors in some patients may cause symptomatic hypotension.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C.
Keep out of reach of children.
Shelf life - 5 years.
